Recombinant adeno-associated virus (rAAV) vectors are generally considered safe. No side-effects have been reported in the many in vivo studies designed to assess the efficacy of rAAV vectors.
Recombinant adeno-associated virus (rAAV) vectors are generally considered safe. No side-effects have been reported in the many in vivo studies designed to assess the efficacy of rAAV vectors. 1 Wild-type AAV (wtAAV) is not associated with any disease and the virus integrates with high frequency into a single site on human chromosome 19. However, the site specificity is lost in rAAV vectors and they have been shown to either persist as episomes or to integrate randomly into the host genome. [2] [3] [4] [5] Therefore, the potential for rAAV to have adverse sideeffects due to insertional mutagenesis may exist.
In this issue of Gene Therapy, Daly et al 6 report on the long-term (1 year) efficacy of intravenous neonatal rAAV treatment for murine mucopolysaccharidosis type VII (MPSVII). Following submission of the paper, three of five rAAV-treated MPSVII mice that were part of a longevity study were killed at approximately 18 months of age for histochemical, biochemical, and histopathological analyses. All of the animals appeared healthy and the three animals killed were chosen at random. Interest- ingly, the average GUSB-specific activities in the liver, spleen, kidney, heart, lung, brain, and serum were virtually identical to those measured in other treated MPSVII animals analyzed at 1 year. 6 At necropsy, two of the three animals had obvious circumscribed 1 to 2 cm in diameter tan-brown tumor nodules beneath the capsular surface of the liver. Following this unexpected discovery, the remaining two rAAV-treated MPSVII mice and eight age-matched normal controls were killed and examined. In addition, tissue from animals from the same study that had died or been killed earlier in the experiment were retrospectively examined for abnormalities. In all, six treated MPSVII animals with tumors were discovered (see Table 1 ). Five animals had hepatocellular carcinomas (HCC) (Figure 1a-c) , one had a metastatic angiosarcoma (AS) (Figure 2a-c) , and one of the five that had HCC also had an angiosarcoma. None of the eight age-matched controls had gross lesions at 18 months of age.
Several hypotheses could explain the formation of the tumors. The first hypothesis is that MPSVII mice are predisposed to tumors. However, since untreated MPSVII mice have a reduced lifespan (6 to 10 months), 6-8 they may not live long enough to develop neoplasms. To address the possibility that the tumors might be strainspecific or specific to older MPSVII animals that have survived because of treatment, four groups of mice were examined histologically for tumors ( Table 2 ). They include: (1) the rAAV-treated MPSVII mice; (2) the normal untreated controls from the efficacy study; (3) mutants that received bone marrow transplantation at birth following 100 rads of gamma radiation; and (4) mutants that received non-ablative bone marrow transplantation at birth. We also examined transgenic mice that harbor the same expression cassette encoded by the rAAV vector 9, 10 to evaluate the possibility that overexpression of human GUSB is oncogenic. All of the experiments described above were performed in mice on the same genetic background (C57Bl/6), except for a mutation in the minor histocompatibility locus bm1 in the animals not receiving bone marrow transplantation. Only the rAAV-treated MPSVII mice exhibited HCC or angiosarcomas, though one of the bone marrow transplanted animals that received radiation had a pulmonary adenocarcinoma. These data are consistent with previous bone marrow transplantation and enzyme replacement studies where the tumor incidence is low. 8, [11] [12] [13] [14] The only example of HCC described in these studies occurred in a 494-dayold normal animal receiving irradiation and bone marrow transplantation. 8 None of the treated MPSVII mice developed HCC. These results suggest that the tumors found in the current study are unique to animals receiving rAAV. However, we have not evaluated the tumorigenic potential of rAAV in normal mice. Studies to evaluate the toxicity of rAAV in nomal animals is currently underway.
Figure 1 Morphology of hepatocellular carcinomas observed in rAAV-treated MPSVII mice. (a) A normal mouse liver has hepatocytes aligned in regular cords and portal spaces (arrowhead). Kupffer cells line the normal sinusoids and there are occasional Ito cells. Hepatocytes are regular in size and have small nuclei with inconspicuous nucleoli. Mitotic figures are not seen in the normal liver (toluidine blue, 1 cm = 31 microns). (b) The interface (arrowhead) between a tumor nodule (bottom) and normal liver (top) is distinct, although there is no tumor capsule. The neoplastic tumor cells in the nodule have marked pleomorphism with variation in cell size and large bizarre nuclei (arrow) in contrast to the regularly sized hepatocytes in the adjacent normal liver (toluidine blue, 1 cm = 31 microns). (c) Although there are areas of preserved liver cell cords, the neoplastic cells in the grossly
It is also possible that MPSVII mice could be at increased risk for liver tumors if they have an increased hepatocyte replication rate. To determine the fraction of hepatocytes undergoing replication, young adult animals (MPSVII mice, normal mice, and transgenic mice overex- pressing GUSB) were given BrdU intraperitoneally (i.p.) and killed 5 to 6 h later. The livers were harvested, sectioned, and stained for BrdU. The frequency of BrdUpositive hepatocytes in all groups of mice were similar (approximately 20 per cm 2 ). However, MPSVII mice had more total positive cells in the liver (about three-fold more). The increased number of replicating cells reflected infrequent aggregates of small BrdU-positive cells morphologically consistent with lymphocytes. By H&E staining, normal, MPSVII, and transgenic animals had similar numbers of lymphocyte aggregates. Therefore, the only difference we detected between the three groups was an increase in DNA replication and presumably cell division in the lymphocyte population in MPSVII mice. The significance of this finding is not clear. Although this type of finding could be due to an infectious agent, none were identified during the course of this study in sentinel animals housed in the same room as the rAAV-treated MPSVII animals. Importantly, no rAAV-treated MPSVII mice were similarly analyzed to determine if the lymphocyte proliferation is corrected or worsened by rAAV treatment.
To evaluate the possibility that the tumors in rAAVtreated MPSVII mice were induced by rAAV, we quantitated the rAAV genome in the tumor cells. DNA was extracted from the tumors, from normal-appearing liver from animals with tumors, and from pieces of liver taken from rAAV-treated animals without tumors. The rAAV genome was quantified by real-time PCR on a PE/ABI 7700 instrument (Table 3) . A FAM-labeled fluorescent probe specific for the enhancer/promoter cassette was used to assess the vector copy number. The diploid genome number was assessed with a VIC-labeled fluorescent probe specific for the murine glyceraldehyde-3-phosphate dehydrogenase gene (GAPDH). None of the tissue samples analyzed had more than 0.113 copies of our rAAV cassette per cell, and several of the samples had less than one copy per 1000 diploid genomes, the sensitivity of this assay. These data suggest that the tumors were not caused by an integration event resulting in clonal expansion of a transformed cell. In that case the quantitative PCR results would theoretically yield a number greater than or equal to one for the number of rAAV genomes per host genome. However, these data do not exclude rAAV as the causative agent for the tumors in the rAAV-treated mice.
As stated previously, there was no evidence before this study of rAAV-associated toxicity. A relatively large Gene Therapy The number of rAAV genomes per diploid genome found in each sample was determined by a Taqman PCR assay detecting the chicken beta-actin promoter and the CMV enhancer used in our rAAV construct and using a GAPDH primer-probe set to determine diploid genome number. The assay is sensitive to about 0.001 copies per cell. Normal tissue represents samples taken from the normalappearing portion of the liver of the treated animal. Tumor tissue represents tissue taken from the liver tumor. Two animals did not present liver tumors. The average copies per genome for the normal tissue and the tumor tissue are not significantly different. These are the total number of animals that received each treatment and were killed after 11, 12, and 13 months, respectively. All meta-analysis comparisons were performed using the 2 -test.
Gene Therapy number of adult and newborn animals, including those described by Song et al 15 in this issue, were injected intravenously with a variety of vectors and were subsequently examined for the presence of toxicity, particularly hepatic toxicity (Table 4 ). These data indicate that 41 mice, receiving doses of 3.2 × 10 9 to 5.2 × 10 9 infectious units (i.u.) of rAAV and being killed 12 to 16 months later, had no evidence of liver pathology. Meta-analysis indicated that the tumor incidence in these animals differed significantly (P Ͻ 0.05) from the incidence observed in the rAAVtreated MPSVII mice. Unfortunately, this study was not originally designed to test toxicity: several strains of mice, many rAAV dosages, and several different vector constructs were used. However, animals injected as neonates or injected via the portal vein (Table 4 ) did receive vectors containing the same rAAV backbone and promoter as that used in the MPSVII study 6, 9, 10 and none developed tumors. In addition, all of the rAAV preparations used in the studies described in Table 4 and in the MPSVII study were packaged and purified using the same techniques at the University of Florida Vector Core Facility. 16 This suggests, but does not prove that there were no infections or chemical agents unique to the rAAV preparations used in the MPSVII study. If there was a common tumorigenic contaminant in the preparations used for the studies described here, tumors should have been observed in all of the long-term studies. Although not all of these rAAV preparations were tested for adenovirus contamination, there was no infectious adenovirus used in the production of these preparations. Previous rAAV preparations produced at the University of Florida Vector Core Facility by this method were free of adenovirus contamination. Taken as a whole, these data suggest that rAAV is not overtly toxic, but it does not exclude a relationship between our rAAV vector and the tumors observed in the rAAV-treated MPSVII mice.
Based on the above experiments, it is still impossible to determine whether or not the tumors identified in the rAAV-treated mice were a consequence of the rAAV treatment. Age-matched control mice and MPSVII mice from previous studies of other therapies have not developed hepatocellular carcinomas or angiosarcomas. In addition, large numbers of mice have been exposed to other rAAV vectors without developing these tumors, and the PCR results are not consistent with a simple model of insertional mutagenesis followed by clonal expansion. However, the observation of tumors in rAAVtreated MPSVII mice highlights the necessity of a detailed long-term study designed to determine the tumorigenic potential of rAAV-based gene transfer vectors.
